United States set
Menu Shopping cart $0 Search
Distributed product

Urine Pre-Clinical CartiLaps® ELISA (CTX-II)

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:C-terminal telopeptide II, carboxy-terminal collagen II crosslinks
Cat. No. Size Price

AC-09F1 96 wells $1423,5
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antigen


The Urine Pre-Clinical CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen (CTX-II) in non-human urine and cell culture supernatant. The test is intended for research use only and not for use in diagnostic procedures.

Scientific Description:

Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage. In non-human urine, the CTX-II fragments can be quantified by Urine Pre-Clinical CartiLaps® EIA, which in addition is applicable for cell culture supernatants.


Urine, Cell culture supernatant

Sample Requirements

10 µL (Pre-diluted (1+3)


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0-100 μg/L

Limit of Detection

0.75 μg/L



  • Animal Models of Rheumatoid Arthritis and Osteoarthritis
  • Easy, non-invasive quantification of cartilage degradation
  • Strong association to indexes of joint damage, e.g. cartilage erosion
  • Demonstration of Chondroprotective Effect of Drugs
  • Rapid response to chondroprotective drugs (within 1-2 weeks)
  • Early response in CTX-II is highly correlated to histological endpoints
  • CTX-II can be quantified in relevant cartilage explant culture supernatant human origin and animal models
  • CTX-II is elevated in both RA and OA rat models
    -CTX-II levels are associated with disease activity in RA and OA, primarily indexes of structural damage
  • Useful for dynamic monitoring of cartilage in multiple species

Research topic

Bone and cartilage metabolism, Extracellular matrix

Product References (1)


  • Henrotin Y, Bannuru R, Malaise M, Ea HK, Confavreux C, Bentin J, Urbin-Choffray D, Conrozier T, Brasseur JP, Thomas P, Hick AC, Marinello A, Giordan N, Richette P. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study. BMC Musculoskelet Disord. 2019 Jun 18;20(1):293. doi: 10.1186/s12891-019-2667-0. PubMed PMID: 31215422. PubMed CentralPMCID: PMC6580647. See more on PubMed
Related Products Docs